<DOC>
	<DOCNO>NCT00225875</DOCNO>
	<brief_summary>The goal study evaluate clinical effectiveness rituximab adult chronic immune thrombocytopenic purpura ( &gt; =6 month evolution ) severe ( platelet &lt; = 30x109/L ) candidate splenectomy . The objective obtain treatment rituximab satisfactory response one year , define number platelet higher 50x109/L least 2 time superior persistent initial figure without treatment one year end treatment .</brief_summary>
	<brief_title>Study Effectiveness Rituximab Adults With Chronic Severe Immune Thrombocytopenic Purpura Candidate Splenectomy</brief_title>
	<detailed_description>Adults immune thrombocytopenic purpura evolution generally chronic define persistence thrombocytopenia 6 month diagnosis . The treatment base splenectomy propose majority team platelet low 30x109/L . The splenectomy effective 70 80 % patient whereas medicamentous treatment make possible obtain comparable result . Nevertheless , expose immediate post-operative complication risk mortal fulminant infection encapsulate germ , particular pneumococcus . However , long-term effectiveness discuss risk relapse would reach 50 % certain team . The rituximab could alternative splenectomy great frequency effectiveness good tolerance short medium term . None medicamentous treatment usually suggest alternative splenectomy ( disulone , danazol , immunosuppressor ) indeed make possible obtain answer prolonged stop therapeutic significant number case . Moreover , use immunosuppressor cyclophosphamide , azathioprine ciclosporine appear contestable stage disease potential severity side effects.The primary endpoint satisfactory response one year , define figure plate &gt; =50x109/L least 2 time superior initial , persistent figure without treatment one year stop treatment rituximab . Secondary objective incomplete response one year , define figure platelet &gt; = 30x109/L &lt; 50x109/L least twice figure initial &gt; 50x109/L low twice persistent initial figure without treatment one year end treatment rituximab . Splenectomy one year satisfactory Response 2 year incomplete Response 2 year Splenectomies 2 year Tolerance treatment .</detailed_description>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Platelets &lt; = 30x109/L absence agglutinat Evolution PTAI &gt; = 6 month start date diagnosis Myélogramme normal rich mégacaryocytes Age &gt; =18 year Among patient treatment prescribe ( particular corticoid intravenous immunoglobulin ) effectiveness , even transitory , diagnosis ITP confirm isotopic study 1/2 life plate . Refusal inform enlightened assent write . Intermittent ITP define occur transitory period remission variable length thrombocytopenia . Sick splenectomized whatever reason Splénomégalie Absence vaccination pneumococcus Absence vaccination Haemophilus influenzae Previous treatment rituximab Administration treatment know active ITP corticoid 30 day precede inclusion CIVD and/or weaken haemolytic schizocytes Serology VIH positive VHC , Ag positive HBs Rate ALAT ASAT high twice high limit normal laboratory Associated autoimmune anomaly : Anti DNA and/or anti ECT ( ENA ) and/or anti Ro ( SSA ) The presence isolate antibody anti core ( nuclear anti factor ) criterion exclusion . Anticoagulant circulate lupic type and/or antibody anticardiolipines antecedent thrombosis spontaneous miscarriage repetition ( isolated presence criterion exclusion ) Other autoimmune disease : lupus ( least 4 criterion ACR ) , polyarthrite chronic evolutionary , disease Biermer , affect thyroid , weaken haemolytic autoimmune . Pregnant woman , breast feeding , woman genital work life effective absence contraception throughout treatment 12 month stop treatment . Evolutionary previous cancer malignant hemopathy Oversensitiveness murine protein</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2005</verification_date>
	<keyword>Autoimmune thrombocytopenic purpura</keyword>
	<keyword>Rituximab</keyword>
</DOC>